Access for the terminally ill to experimental medical innovations: a three-pronged threat

MeSH terms

• Bias
• Clinical Trials, Phase I as Topic
• Drug Evaluation* / economics
• Drug Evaluation* / ethics
• Drug Evaluation* / legislation & jurisprudence
• Drug Industry / economics
• Drug Industry / ethics
• Drug Industry / legislation & jurisprudence
• Drugs, Investigational* / standards
• Drugs, Investigational* / therapeutic use
• Ethical Theory
• Evidence-Based Medicine
• Female
• Health Services Accessibility* / ethics
• Health Services Accessibility* / legislation & jurisprudence
• Humans
• Liability, Legal
• Lobbying
• Marketing of Health Services* / economics
• Marketing of Health Services* / ethics
• Marketing of Health Services* / legislation & jurisprudence
• Mass Media
• Patient Rights*
• Social Responsibility*
• Terminally Ill* / psychology
• Therapies, Investigational / standards
• Treatment Outcome*
• United States
• United States Food and Drug Administration
• Unnecessary Procedures